Skip to main content

Table 2 m6A inhibitors have different targets and mechanisms

From: The importance of N6-methyladenosine modification in tumor immunity and immunotherapy

Cancer/Disease

Drug

Target

Role

Mechanism

AML

STM2457

METTL3

Inhibitor

Weaken the proliferation of AML stem cells or leukemia

SPI1

METTL14

Regulator

Promote terminal myeloid differentiation of normal HSPCs/AML

Inhibit AML cell survival

CS1/CS2

FTO

Inhibitor

Increase the sensitivity of AML cells to T cell toxicity

R-2HG

FTO

Inhibitor

Inhibit the proliferation of AML and weaken aerobic glycolysis

in sensitive leukemic cells

FB23-2

FTO

Inhibitor

Suppress proliferation and promote the differentiation of AML

Rhein

FTO

Inhibitor

Overcome tyrosine kinase inhibitor resistance

GBM

MA/MA2

FTO

Inhibitor

Suppress the growth and self-renewal of GSCs

Melanoma

ALK-04

ALKBH5

Inhibitor

Regulate the express of Mct4/Scl16a3 and lactic acid

BC

MO-I-500

FTO

Inhibitor

Suppress survival of BC cells by decreasing IRX3 proteins

LUAD

PKE

Sorafenib

YTHDC2

Regulator

Suppress SLC7A11-dependent antioxidant function

Testicular damage

MEHP

FTO

Inhibitor

Regulate reduction of testosterone and increase of apoptosis